Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 39.1 Cr.
- Current Price ₹ 49.8
- High / Low ₹ 63.4 / 38.1
- Stock P/E 9.61
- Book Value ₹ 22.4
- Dividend Yield 0.00 %
- ROCE 15.0 %
- ROE 23.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 48.4 to 62.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 121 | 128 | |
| 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 117 | 119 | |
| Operating Profit | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 8 |
| OPM % | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 3% | 6% |
| -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | -4 | |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 0 |
| Tax % | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | 25% | 56% |
| 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | |
| EPS in Rs | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.58 | 0.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 35% |
| 3 Years: | 19% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 37% |
| 5 Years: | 41% |
| 3 Years: | 44% |
| TTM: | 105% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 26% |
| 3 Years: | 5% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| Last Year: | 23% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 10 | 10 |
| 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 33 | 31 | |
| 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 26 | 23 | |
| Total Liabilities | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 72 |
| 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | 8 | |
| CWIP | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | 64 | |
| Total Assets | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 72 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | 2 | -7 | 5 | |
| -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | 2 | -0 | |
| -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | -2 | 5 | -8 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -3 |
| Free Cash Flow | 0 | 1 | -2 | -7 | 2 | 2 | -1 | 2 | -2 | 2 | -7 | 4 |
| CFO/OP | 28% | -146% | -50% | 168% | 184% | 157% | -11% | 78% | 2% | 60% | -144% | 58% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 | 39 | 63 |
| Inventory Days | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 | 121 | 102 |
| Days Payable | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 | 56 | 41 |
| Cash Conversion Cycle | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 | 104 | 123 |
| Working Capital Days | 32 | 69 | 114 | 214 | 108 | 104 | 114 | 37 | 1 | 10 | 36 | 32 |
| ROCE % | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 12% | 12% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings (FOB value of exports) INR Lakhs |
|
|||||||||
| Foreign Exchange Outgo (CIF value of imports) INR Lakhs |
||||||||||
| Number of permanent employees employees |
||||||||||
| Export revenue as % of total revenue % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Submission Of Report On Re-Lodgement Of Transfer Requests Of Physical Shares Under Special Window
2d - Aarthi Consultants reported nil re-lodgement requests for physical shares during June 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Jul - Regulation 74(5) compliance certificate for dematerialization, quarter ended 30 June 2026.
- Closure of Trading Window 25 Jun
-
Submission Of Newspaper Clipping Pursuant To SEBI Circular No. SEBI/HO/38/13/11(2)2026- MIRSD-Pod/1/3750/2026 Dated January 30, 2026
15 Jun - Published shareholder notice on special window for transfer and dematerialisation of physical securities.
-
Submission Of Report On Re-Lodgement Of Transfer Requests Of Physical Shares Under Special Window
12 Jun - Aarthi Consultants reported nil re-lodgement requests for physical shares in April and May 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally